Clinical trial
Thiotepa Combined With TBI, Fludarabine, and Etoposide as Intensive Pre-treatment for Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Refractory/Recurrent or High-risk Acute Leukemia: a Multi-center, Prospective, Single-arm Clinical Study
NCT07920796 is registered in ClinicalTrials.gov with Guangdong Second Provincial General Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- Thiotepa Combined With TBI, Fludarabine, and Etoposide as Intensive Pre-treatment for Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Refractory/Recurrent or High-risk Acute Leukemia: a Multi-center, Prospective, Single-arm Clinical Study
- Lead sponsor
- Guangdong Second Provincial General Hospital
- Phase
- Phase 2
- Overall status
- Enrolling by invitation
- Start date
- June 16, 2026
- Completion date
- July 31, 2029
- Enrollment
- 50 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
acute leukemia refractory, acute leukemia, high risk, acute leukemia, relapsed
Arms
As registered; 1 arm.
-
Thiotepa/TBI/Fludarabine/Etoposide Conditioning Plus Allo-HSCT
Participants receive total body irradiation, thiotepa, fludarabine, and etoposide on prespecified days before their first allogeneic hematopoietic stem cell transplantation, followed by protocol-specified assessments through 24 months after transplantation.
Primary endpoints
Registered primary outcome measures; 1 primary.
-
One-Year Disease-Free Survival Rate After Allogeneic Transplantation
Proportion of participants alive without leukemia relapse at 1 year after allo-HSCT; relapse or death from any cause is an event.
Patents and exclusivity
By drug, as the FDA Orange Book declares its patents.
-
ETOPOSIDE
- US RE35524; expires May 17, 2010; assignee Bristol Myers Squibb Co
-
FLUDARABINE
- US 4357324; expires November 2, 2001; assignee Department of Health and Human Services
-
Thiotepa
- US 11975013; expires August 16, 2041; assignee SHORLA PHARMA LTD.
- US 12622921; expires August 16, 2041; assignee not stated
- US 9931458; expires May 31, 2037; assignee ADIENNE PHARMA &BIOTECH SA
Lead sponsor's other trials
Guangdong Second Provincial General Hospital, most recent start first.
+9 more trials See the organization page
Similar trials
Same condition (Recurrence) and phase, most recent start first.
+892 more trials See the condition page